Michalina Jagodzińska1, Małgorzata Szperl2, Joanna Ponińska2, Agnieszka Kosiec2, Robert Gajda3, Piotr Kukla4, Elżbieta Katarzyna Biernacka5. 1. Student Research Group, Institute of Cardiology, Warsaw, Poland. 2. Department of Molecular Biology, Institute of Cardiology, Warsaw, Poland. 3. Medical Center "Gajda-Med", Pułtusk, Poland. 4. Department of Cardiology and Internal Medicine, Specialist Hospital, Gorlice, Poland. 5. Department of Congenital Cardiac Defects, Institute of Cardiology, Warsaw, Poland.
Abstract
BACKGROUND: Andersen-Tawil Syndrome (ATS) is a channelopathy caused by mutations in KCNJ2 gene. It is characterized by symptoms of ventricular arrhythmias, periodic paralysis or muscle weakness, and dysmorphic features. ATS can present with the triad of symptoms, any combination or none of them. Risk factors for dangerous arrhythmias are unknown. The study assessed the impact of K897T polymorphism in hERG1 gene and H558R polymorphism in SCN5A gene coexisting with R218Q mutation in KCNJ2 in one family on clinical manifestation. METHODS: Family members underwent clinical assessment, ECG and genotyping. Holter monitoring was performed in mutation carriers and additionally in one family member with no mutation, but with K897T polymorphism. RESULTS: Proband with ATS mutation, K897T and H558R polymorphisms and proband's sister with ATS mutation and K897T polymorphism presented following symptoms: loss of consciousness, bidirectional and polymorphic ventricular tachycardia and about 5000 ventricular extrasystoles. Symptoms presented by the member with only the ATS mutation and by member with ATS mutation and H558R polymorphism were not as severe. U wave appeared in all examined family members regardless of the mutation presence. Studied individuals with ATS mutation had the T-peak-U-peak interval longer than 200 ms. In all ATS mutation carriers it was longer than in family members with no mutation. T-peak-T-end interval was the longest (>120 ms) in members with coexisting mutation and K897T polymorphism. CONCLUSION: ATS severity possibly depends on other genes' polymorphisms. In the presented family, it could depend on the presence of K897T polymorphism in hERG1.
BACKGROUND: Andersen-Tawil Syndrome (ATS) is a channelopathy caused by mutations in KCNJ2 gene. It is characterized by symptoms of ventricular arrhythmias, periodic paralysis or muscle weakness, and dysmorphic features. ATS can present with the triad of symptoms, any combination or none of them. Risk factors for dangerous arrhythmias are unknown. The study assessed the impact of K897T polymorphism in hERG1 gene and H558R polymorphism in SCN5A gene coexisting with R218Q mutation in KCNJ2 in one family on clinical manifestation. METHODS: Family members underwent clinical assessment, ECG and genotyping. Holter monitoring was performed in mutation carriers and additionally in one family member with no mutation, but with K897T polymorphism. RESULTS: Proband with ATS mutation, K897T and H558R polymorphisms and proband's sister with ATS mutation and K897T polymorphism presented following symptoms: loss of consciousness, bidirectional and polymorphic ventricular tachycardia and about 5000 ventricular extrasystoles. Symptoms presented by the member with only the ATS mutation and by member with ATS mutation and H558R polymorphism were not as severe. U wave appeared in all examined family members regardless of the mutation presence. Studied individuals with ATS mutation had the T-peak-U-peak interval longer than 200 ms. In all ATS mutation carriers it was longer than in family members with no mutation. T-peak-T-end interval was the longest (>120 ms) in members with coexisting mutation and K897T polymorphism. CONCLUSION:ATS severity possibly depends on other genes' polymorphisms. In the presented family, it could depend on the presence of K897T polymorphism in hERG1.
Authors: N M Plaster; R Tawil; M Tristani-Firouzi; S Canún; S Bendahhou; A Tsunoda; M R Donaldson; S T Iannaccone; E Brunt; R Barohn; J Clark; F Deymeer; A L George; F A Fish; A Hahn; A Nitu; C Ozdemir; P Serdaroglu; S H Subramony; G Wolfe; Y H Fu; L J Ptácek Journal: Cell Date: 2001-05-18 Impact factor: 41.582
Authors: S L Venance; S C Cannon; D Fialho; B Fontaine; M G Hanna; L J Ptacek; M Tristani-Firouzi; R Tawil; R C Griggs Journal: Brain Date: 2005-09-29 Impact factor: 13.501
Authors: M R Donaldson; J L Jensen; M Tristani-Firouzi; R Tawil; S Bendahhou; W A Suarez; A M Cobo; J J Poza; E Behr; J Wagstaff; P Szepetowski; S Pereira; T Mozaffar; D M Escolar; Y-H Fu; L J Ptácek Journal: Neurology Date: 2003-06-10 Impact factor: 9.910
Authors: Eeva Pietilä; Heidi Fodstad; Elmo Niskasaari; Päivi J Laitinen P; Heikki Swan; Markku Savolainen; Y Antero Kesäniemi; Kimmo Kontula; Heikki V Huikuri Journal: J Am Coll Cardiol Date: 2002-08-07 Impact factor: 24.094
Authors: Gregor Andelfinger; Andrew R Tapper; Richard C Welch; Carlos G Vanoye; Alfred L George; D Woodrow Benson Journal: Am J Hum Genet Date: 2002-07-29 Impact factor: 11.025
Authors: Christopher Newton-Cheh; Chao-Yu Guo; Martin G Larson; Stacy L Musone; Aarti Surti; Amy L Camargo; Jared A Drake; Emelia J Benjamin; Daniel Levy; Ralph B D'Agostino; Joel N Hirschhorn; Christopher J O'donnell Journal: Circulation Date: 2007-08-20 Impact factor: 29.690
Authors: Michalina Krych; Elżbieta Katarzyna Biernacka; Joanna Ponińska; Piotr Kukla; Artur Filipecki; Robert Gajda; Can Hasdemir; Charles Antzelevitch; Agnieszka Kosiec; Małgorzata Szperl; Rafał Płoski; Maria Trusz-Gluza; Katarzyna Mizia-Stec; Piotr Hoffman Journal: J Cardiol Date: 2017-03-21 Impact factor: 3.159
Authors: Robert Gajda; Beat Knechtle; Anita Gębska-Kuczerowska; Jacek Gajda; Sebastian Stec; Michalina Krych; Magdalena Kwaśniewska; Wojciech Drygas Journal: Int J Environ Res Public Health Date: 2022-08-19 Impact factor: 4.614